



Treatment of Schizophrenia

Efficacy was established in four 6-week controlled studies of adult patients with schizophrenia. The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

IMPORTANT SAFETY INFORMATION FOR LATUDA

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4-5% compared to a rate of 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Please see enclosed full Prescribing Information, including Boxed Warning.

Program Overview

Treating schizophrenia with antipsychotics is not a “one-size-fits-all” proposition. No single agent is right for every patient because individual responses to medications differ markedly. The material presented is directed to psychiatrists, psychiatric nurse practitioners, and clinicians who care for adult patients with schizophrenia.

This therapeutic awareness program will provide the mental health care community with a thorough understanding of Latuda (lurasidone HCl). To achieve this goal, Stephen M. Stahl, MD, PhD and other expert faculty will guide participants through explorations of the indication and usage, clinical pharmacology, efficacy data, and safety and tolerability profile of LATUDA.

The program will include a plenary lecture delivered by a prominent opinion leader in the field of psychiatry. The lecture will feature animations and quizzes to engage the audience and bring the scientific story to life. This session will be followed by an immersive learning experience: participants will form teams and rotate between activity stations that will test their knowledge of LATUDA. The multimedia sessions will spark an educational and competitive, yet fun atmosphere through games, real-life case studies, and a poster “scavenger hunt.”

With the information presented in this program, clinicians may obtain greater insight into whether LATUDA is appropriate for the treatment of their adult patients living with schizophrenia. Clinicians now have another therapeutic option when considering the treatment needs of their patients with schizophrenia.

Program Learning Objectives

- To introduce LATUDA and discuss the following:
 - Indication and usage
 - Clinical pharmacology
 - Efficacy
 - Safety and tolerability profile
- To test knowledge of LATUDA through interactive learning stations (games, case studies, and poster session)

To learn more or register, please visit www.sunovionmeetings.com or call 855-621-5113.